|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.79 CHF | -1.13% |
|
-4.10% | +15.39% |
| Sep. 05 | NOVARTIS : Goldman Sachs no longer Buy | CF |
| Sep. 05 | Such a long wait |  |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
| Capitalization | 236B 199B | P/E ratio 2024 * |
21.1x | P/E ratio 2025 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise value | 249B 209B | EV / Sales 2024 * |
4.99x | EV / Sales 2025 * | 4.72x |
| Free-Float |
85.22% | Yield 2024 * |
3.23% | Yield 2025 * | 3.35% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novartis AG
More recommendations
More press releases
| 1 day | -1.12% | ||
| 1 week | -4.10% | ||
| Current month | -4.10% | ||
| 1 month | +4.97% | ||
| 3 months | +3.10% | ||
| 6 months | +7.54% | ||
| Current year | +15.39% |
1 week
97.60
102.72
1 month
93.72102.72
Current year
83.63102.72
1 year
83.00102.72
3 years
72.84102.72
5 years
65.09102.72
10 years
65.09103.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 04-12-31 | |
| Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Sawyers
BRD | Director/Board Member | 65 | 12-12-31 |
Bill Winters
BRD | Director/Board Member | 63 | 12-12-31 |
| Chairman | 68 | 12-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | - | |
| 5.57% | 18 M€ | +7.76% | - | |
| 3.79% | 2 M€ | -25.75% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.15% | -4.10% | +12.29% | +17.10% | 236B | ||
| -3.55% | -2.92% | +63.52% | +251.69% | 822B | ||
| -0.73% | -6.68% | +31.90% | +174.85% | 583B | ||
| -1.42% | +0.46% | +2.68% | -5.74% | 397B | ||
| -2.11% | -1.19% | +32.01% | +72.78% | 341B | ||
| +2.41% | +0.96% | +10.31% | +53.49% | 301B | ||
| +0.45% | -5.33% | +18.48% | +45.36% | 256B | ||
| -0.56% | -4.42% | +8.76% | -25.33% | 262B | ||
| -1.90% | -2.01% | +27.70% | +43.29% | 174B | ||
| +0.42% | -0.73% | -19.42% | -39.13% | 162B | ||
| Average | -0.17% | -2.11% | +18.82% | +58.84% | 353.35B | |
| Weighted average by Cap. | -0.14% | -2.29% | +27.59% | +101.20% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 49.83B 41.9B | 52.15B 43.85B |
| Net income | 11.1B 9.33B | 12.58B 10.58B |
| Net Debt | 12.5B 10.51B | 9.86B 8.29B |
More financial data
* Estimated data
Employees
76,057
Sector
Pharmaceuticals
Calendar
Related indices
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-06 | 97.71 CHF | -1.21% | 165,364 |
| 24-09-05 | 98.91 CHF | -1.99% | 4,177,746 |
| 24-09-04 | 100.92 CHF | -0.43% | 3,728,693 |
| 24-09-03 | 101.36 CHF | -1.30% | 3,324,825 |
| 24-09-02 | 102.70 CHF | +0.57% | 2,589,802 |
Delayed Quote Swiss Exchange, September 06, 2024 at 03:14 am EDT
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
116.74USD
Average target price
116.83USD
Spread / Average Target
+0.08%
- Stock Market
- Equities
- NOVN Stock
